

2024 Current Fiscal Year Report: Uniform Formulary Beneficiary Advisory Panel

Report Run Date: 04/26/2024 02:00:24 PM

1. Department or Agency

Department of Defense

2. Fiscal Year

2024

3. Committee or Subcommittee

Uniform Formulary Beneficiary
Advisory Panel

3b. GSA

Committee No.

9484

4. Is this New During Fiscal Year?

No

5. Current Charter

08/01/2022 08/01/2024

6. Expected Renewal Date

7. Expected Term Date

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

10 U.S.C. § 1074g(c)

13. Effective Date

10/05/1999

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program
Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a.

Open

0

17b. Closed

0

17c. Partially Closed

0

Other Activities

0

17d. Total

0

Meetings and Dates

No Meetings

Current Next

FY

FY

| | |
|---|---------------|
| 18a(1). Personnel Pmts to Non-Federal Members | \$0.00 \$0.00 |
| 18a(2). Personnel Pmts to Federal Members | \$0.00 \$0.00 |
| 18a(3). Personnel Pmts to Federal Staff | \$0.00 \$0.00 |
| 18a(4). Personnel Pmts to Non-Member Consultants | \$0.00 \$0.00 |
| 18b(1). Travel and Per Diem to Non-Federal Members | \$0.00 \$0.00 |
| 18b(2). Travel and Per Diem to Federal Members | \$0.00 \$0.00 |
| 18b(3). Travel and Per Diem to Federal Staff | \$0.00 \$0.00 |
| 18b(4). Travel and Per Diem to Non-member Consultants | \$0.00 \$0.00 |
| 18c. Other(rents,user charges, graphics, printing, mail, etc.) | \$0.00 \$0.00 |
| 18d. Total | \$0.00 \$0.00 |
| 19. Federal Staff Support Years (FTE) | 0.00 0.00 |

20a. How does the Committee accomplish its purpose?

The Panel will meet an estimate of four times a year to review and comment on the development of the Uniform Formulary by the DoD Pharmacy and Therapeutics Committee. The Director, Defense Health Agency is required to consider the comments of the panel before making his final decision.

20b. How does the Committee balance its membership?

The Panel's membership includes family members of active duty and retired military personnel, members of retiree organizations, TRICARE healthcare contractors, and medical professionals from outside of DoD.

20c. How frequent and relevant are the Committee Meetings?

Per the Charter, the estimated number of Panel meeting is 4 per year. DoD implemented its Congressionally-mandated 3-tier Uniform Formulary (UF) in 2005 which required development of a transparent formulary management process that accesses medications for formulary status based on an evidence-based clinical and cost-effectiveness evaluation; open/equitable price competition; and to establish the Beneficiary Advisory Panel (BAP) which provides an opportunity for beneficiaries to comment on the DoD Pharmacy and Therapeutics Committee's formulary recommendations before approval by the DHA Director. The BAP concept is unique to DoD. It provides transparency and credibility from a beneficiary perspective to the UF process. Unlike private sector health plans, the DoD uses more disclosure of the evidence presented and allows beneficiaries to provide input before implementation of formulary changes. A major focus of the BAP is the process of formulary decision implementation, especially the process of communication with the 9.7 million TRICARE beneficiaries. For example, the BAP can recommend a longer implementation period for medications moved to Non-Formulary (Tier 3) to balance between allowing necessary time for beneficiary notification versus cost considerations. Moreover, feedback from the BAP was instrumental in the DoD's decision to start sending targeted letters to affected beneficiaries during the up to 180-day implementation period. Implementation periods have been lengthened on several occasions supporting communication with beneficiaries.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Mandated by law to review and comment on recommendations by the DoD Pharmacy and Therapeutics Committee regarding DoD's Uniform Formulary.

20e. Why is it necessary to close and/or partially closed committee meetings?

Meetings are not closed to the public unless the Department of Defense determines that items on the planned agenda meet the closed meeting provisions of 5 U.S.C. § 552b(c). Pursuant to DoD policy closed meetings can only be authorized by the DoD Sponsor (i.e., the Under Secretary of Defense for Personnel and Readiness), and only after consultation with the Office of the Department of Defense General Counsel.

21. Remarks

Mr. Keith Reed departed in FY 2022 due to becoming a Federal lobbyist July 19, 2022. Title 10, U.S. Code, section 1074g(b), requires the Secretary of Defense to establish a Uniform Formulary Beneficiary Advisory Panel (BAP) under the Federal Advisory Committee Act. The estimated number of Panel meetings is four per year. The relationship between the committee and the decision maker is that no specific reports are submitted to the decision maker. Instead, the committee's advice and recommendations are communicated to the committee's decision maker through its meeting minutes. The committee's decision maker reviews these minutes and makes appropriate decisions for the Department of Defense.

Designated Federal Officer

Paul B. Carby DFO

| Committee Members | Start | End | Occupation | Member Designation |
|--------------------------|--------------|------------|---|--|
| Dager, Karen | 01/25/2022 | 01/24/2026 | Health Net Federal Services | Special Government Employee (SGE) Member |
| Dailey, Holly | 04/06/2022 | 04/05/2026 | The Association of the United States Army | Special Government Employee (SGE) Member |
| Du Teil, John | 01/25/2022 | 01/24/2026 | United States Army Warrant Officers Association | Special Government Employee (SGE) Member |
| Guzman, Betsaida | 01/25/2022 | 01/24/2026 | Veterans of Foreign Wars | Special Government Employee (SGE) Member |
| McKeon, Joseph | 01/25/2022 | 01/24/2026 | Humana | Special Government Employee (SGE) Member |
| Meyers, Amanda | 04/06/2022 | 04/05/2026 | Military Officers Association | Special Government Employee (SGE) Member |
| Orfini, Patricia | 04/06/2022 | 04/05/2026 | National Family Member Association | Special Government Employee (SGE) Member |
| Ostrowski, Jon | 01/25/2022 | 01/24/2026 | Non-Commissioned Officers Association | Special Government Employee (SGE) Member |
| Peloquin, Jay | 01/25/2022 | 01/24/2026 | Express Scripts, Inc | Special Government Employee (SGE) Member |
| Schweitzer, Pamela | 01/25/2023 | 01/24/2027 | Pharmacist, COA-USPHS | Special Government Employee (SGE) Member |

Soucy, Jennifer 01/25/2022 01/24/2026 United States Family Health Plan - Martins Point Special Government Employee (SGE) Member

Number of Committee Members Listed: 11

Narrative Description

The Uniform Formulary Beneficiary Advisory Panel provides a forum for input into the development and sustainment of the pharmacy benefit for all Department of Defense (DoD) beneficiaries.

What are the most significant program outcomes associated with this committee?

| | Checked if Applies |
|---|-------------------------------------|
| Improvements to health or safety | <input checked="" type="checkbox"/> |
| Trust in government | <input checked="" type="checkbox"/> |
| Major policy changes | <input type="checkbox"/> |
| Advance in scientific research | <input type="checkbox"/> |
| Effective grant making | <input type="checkbox"/> |
| Improved service delivery | <input type="checkbox"/> |
| Increased customer satisfaction | <input checked="" type="checkbox"/> |
| Implementation of laws or regulatory requirements | <input checked="" type="checkbox"/> |
| Other | <input type="checkbox"/> |

Outcome Comments

NA

What are the cost savings associated with this committee?

| | Checked if Applies |
|-------------------------|-------------------------------------|
| None | <input checked="" type="checkbox"/> |
| Unable to Determine | <input type="checkbox"/> |
| Under \$100,000 | <input type="checkbox"/> |
| \$100,000 - \$500,000 | <input type="checkbox"/> |
| \$500,001 - \$1,000,000 | <input type="checkbox"/> |

\$1,000,001 - \$5,000,000
\$5,000,001 - \$10,000,000
Over \$10,000,000
Cost Savings Other

☐
☐
☐
☐

Cost Savings Comments

The recommendations made by the Panel do not attribute to a cost savings to the Department of Defense.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

1,168

Number of Recommendations Comments

The Panel made 128 recommendations during FY 2023, to address the FY 2023 DoD Pharmacy and Therapeutics Committee meetings. The Panel makes comments to the DoD Pharmacy and Therapeutics Committee recommendations for changes to the Uniform Formulary, implementation timelines, and prior authorization criteria. To date the Panel has made 1256 recommendations. This includes the 128 recommendations made in FY 2023.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

100%

% of Recommendations Fully Implemented Comments

The Director, Defense Health Agency, is required to consider the Panel's comments prior to her final decisions.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

The committee may recommend a shorter or longer implementation period. They may also reject a recommendation. The Director, Defense Health Agency makes the final decision.

Does the agency provide the committee with feedback regarding actions taken to

implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Minutes from the DoD Pharmacy & Therapeutics Committee and Uniform Formulary Beneficiary Advisory Panel are posted and available to Panel members.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

| | |
|-----------------------------------|--------------------------|
| Reorganized Priorities | <input type="checkbox"/> |
| Reallocated resources | <input type="checkbox"/> |
| Issued new regulation | <input type="checkbox"/> |
| Proposed legislation | <input type="checkbox"/> |
| Approved grants or other payments | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

| | |
|---------------------------|-------------------------------------|
| Contact DFO | <input checked="" type="checkbox"/> |
| Online Agency Web Site | <input checked="" type="checkbox"/> |
| Online Committee Web Site | <input checked="" type="checkbox"/> |
| Online GSA FACA Web Site | <input checked="" type="checkbox"/> |
| Publications | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Access Comments

N/A